Inherited and Acquired Risk Factors for Venous Thromboembolic Disease Among Women Taking Tamoxifen to Prevent Breast Cancer
- 1 October 2003
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (19), 3588-3593
- https://doi.org/10.1200/jco.2003.10.111
Abstract
Purpose: Venous thromboembolism (VTE) is of particular concern in women receiving tamoxifen in a chemopreventive setting. We investigate the association between acquired and inherited risk factors for VTE in the International Breast Cancer Intervention Study (IBIS-I) trial of tamoxifen prophylaxis for women at increased risk of breast cancer. Methods: We used a nested case-control study design to investigate the role of tamoxifen and acquired risk factors in the risk of developing a VTE. Results: Tamoxifen was associated with a significantly increased risk of developing a major VTE (odds ratio [OR], 2.1; 95% CI, 1.1 to 4.1). Women who had surgery, immobilization, or fracture in the previous month had a greatly increased risk of developing a major VTE (OR, 4.7; 95% CI, 2.2 to 10.1). Prothrombin and factor V Leiden mutations were found exclusively among control women: factor V Leiden in eight of 159 control women (5.0%) and the prothrombin mutation in three control women (1.9%). Thirty-five women with a VTE...Keywords
This publication has 47 references indexed in Scilit:
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyThe Lancet, 1999
- Molecular Biology and Pathophysiology of APC Resistance: Current Insights and Clinical ImplicationsSeminars in Thrombosis and Hemostasis, 1998
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994